Impact News +++ United Internet: Die Zahlen sind da – Aktie springt an (Der Aktionaer) +++ UNITED INTERNET Aktie -4,63%

NANOVIRICIDES Aktie

>NANOVIRICIDES Aktienkurs

1.48 EUR +3.5% (Tradegate)

Ask: 1.48 EUR / 1344 Stück

Bid: 1.42 EUR / 1413 Stück

Tagesumsatz: 10 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>NANOVIRICIDES Performance

1 Woche: -7,9%

1 Monat: +37,6%

3 Monate: +20,3%

6 Monate: +39,9%

1 Jahr: +21,6%

laufendes Jahr: +12,8%

>NANOVIRICIDES Aktie

Name:

NANOVIRICIDES NEW DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6300873022 / A2PSNF

Symbol/ Ticker:

NV3P (Frankfurt)

Kürzel:

FRA:NV3P, ETR:NV3P, NV3P:GR

Index:

Webseite:

https://www.nanoviricides..

Profil:

Nanoviricides Inc. is a pioneering biotechnology c..
>Volltext..

Marktkapitalisierung:

27.76 Mio. EUR

Unternehmenswert:

26.44 Mio. EUR

Umsatz:

EBITDA:

-7.66 Mio. EUR

Nettogewinn:

-8.19 Mio. EUR

Gewinn je Aktie:

-0.55 EUR

Schulden:

Liquide Mittel:

1.35 Mio. EUR

Operativer Cashflow:

-7.34 Mio. EUR

Bargeldquote:

1.19

Umsatzwachstum:

Gewinnwachstum:

-3.79%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NANOVIRICIDES

Letzte Datenerhebung:

11.11.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 17.43 Mio. St.

Frei handelbar: 96.37%

Leerverk. Aktien: -

Rückkaufquote: -16.51%

Mitarbeiter: 7

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Neutral

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 3.93

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -87.47%

Eigenkaprendite: -99.75%

>Peer Group

Es sind 597 Aktien bekannt.

>NANOVIRICIDES Chart & Kurs - Tradegate

>NANOVIRICIDES News

10.11.25 - 16:00	NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.25 - 14:42	NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial o......

08.11.25 - 14:24	NanoViricides′ NV-387 shows broad antiviral potential, says Zacks (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 14:42	NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT (Accesswire)
	NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"......

03.11.25 - 14:42	NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs......

01.11.25 - 20:36	NanoViricides targets broad-spectrum virus threats – ICYMI (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

29.10.25 - 13:54	Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined S......

27.10.25 - 15:12	NanoViricides′ NV-387 shows potent anti-measles activity, highlighting broad-spectrum potential (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

27.10.25 - 13:54	NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 (Accesswire)
	SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that t......

22.10.25 - 14:54	In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown s......

20.10.25 - 14:54	A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus (Accesswire)
	SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong......

15.10.25 - 14:54	NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that expla......

30.09.25 - 14:54	NanoViricides, Inc. Has Filed its Annual Report (Accesswire)
	Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September ......

09.09.25 - 14:42	NanoViricides to Present at the Life Science Executive Partnering Congress in Boston on September 17, 2025 (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral dru......

18.08.25 - 14:42	NanoViricides: A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the d......

31.07.25 - 03:48	NanoViricides says antiviral candidate NV-387 could address global measles surge (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.25 - 14:39	Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides (Accesswire)
	SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of ......

23.07.25 - 14:42	NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value (Accesswire)
	SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the devel......

21.07.25 - 21:36	NanoViricides says lead antiviral boosted survival in measles-infected mice (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

21.07.25 - 12:42	Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides (Accesswire)
	SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development o......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein alter Affe lernt nicht tanzen. - Weisheiten - Wissen - Wahrheiten aus dem Orient

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram